NEW YORK (Reuters) – Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.
Source:: UKScienceNews
NEW YORK (Reuters) – Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.
Source:: UKScienceNews